WHAT IS CLAIMED IS:

1. Use of ~~an effective amount of a CETP inhibitor~~ dalcetrapib in the preparation of a medicament for the treatment of type 2 diabetes in a subject in need thereof and known to have genotype rs1967309/AA ~~or rs1967309/AG~~, wherein the subject has an HbA1c level that is greater than 7.0% of whole blood.

~~2. The use of claim 1, wherein the CETP inhibitor is: dalcetrapib; torcetrapib; anacetrapib; evacetrapib; obicetrapib; BMS795311; CP-800,569; DLBS-1449; ATH-03; DRL-17822; JNJ-28545595; JNJ-28614872; BAY 19-4789; BAY 38-1315; BAY 60-5521; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate; S-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate; O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate; S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate; S-[2-(pivaloylamino)-4-~~

~~trifluoromethylphenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide; 2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide; N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate; bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide; N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate; S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4-thiocarboxylate; S-[2-[1-(2-~~

~~ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate; S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; or S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate; or a pharmaceutically acceptable salt of any of the foregoing.~~

2~~3~~. The use of claim 1~~ or 2~~, wherein the ~~CETP inhibitor~~ dalcetrapib is to be administered to the subject in an amount ranging from 100 mg to 2400 mg per day.

3~~4~~. The use of claim ~~3~~2, wherein the ~~CETP inhibitor~~ dalcetrapib is to be administered to the subject in an amount ranging from 100 mg to 1800 mg per day.

4~~5~~. The use of claim ~~4~~3, wherein the ~~CETP inhibitor~~ dalcetrapib is to be administered to the subject in an amount ranging from 300 mg to 900 mg per day.

5~~6~~. The use of claim ~~5~~4, wherein the ~~CETP~~ dalcetrapib is to be administered to the subject in an amount of 600 mg per day.

6~~7~~. The use of any one of claims ~~3-6~~2-5, wherein an effective amount of an antidiabetic agent is to be further administered to the subject.

7~~8~~. The use of claim ~~7~~6, wherein the antidiabetic agent is metformin, a sulfonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, GLP-1, a GLP-1 analogue, insulin, an insulin analogue, or a DPP-IV inhibitor, or a pharmaceutically acceptable salt thereof.

8~~9~~. The use of any one of claims 1-~~6~~5, wherein the subject undergoes treatment with an antidiabetic agent.

910. The use of claim 98, wherein the antidiabetic agent is metformin, a sulfonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, GLP-1, a GLP-1 analogue, insulin, an insulin analogue, or a DPP-IV inhibitor, or a pharmaceutically acceptable salt thereof.

~~11. The use of any one of claims 1-10, wherein the subject has an HbA1c level that is equal to or greater than 6.5% of whole blood.~~

~~12. The use of any one of claims 1-11, wherein the subject has an HbA1c level that is equal to or greater than 7.0% of whole blood.~~

1013. The use of any one of claims 1-129, wherein the subject has an HbA1c level that is equal to or greater than 7.5% of whole blood.

1114. The use of any one of claims 1-1310, wherein the subject has a fasting plasma glucose level that is equal to or greater than 126 mg/dL.

1215. The use of any one of claims 1-1411, wherein the subject is an adult human.

1316. The use of any one of claims 1-1411, wherein the subject is a pediatric human.

~~17. A composition comprising an effective amount of a CETP inhibitor for use in the treatment of type 2 diabetes in a subject in need thereof and known to have genotype rs1967309/AA or rs1967309/AG.~~

~~18. The composition for use according to claim 17, wherein the CETP inhibitor is: dalcetrapib; torcetrapib; anacetrapib; evacetrapib; obicetrapib; BMS795311; CP-800,569; DLBS-1449; ATH-03; DRL-17822; JNJ-28545595; JNJ-28614872; BAY 19-4789; BAY 38-1315; BAY 60-5521; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-3-phenylthiopropionate; S-~~

[2-(1-isopentylcyclohexanecarbonylamino)phenyl]3-pyridinethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]chlorothioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]methoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]phenoxy-thioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclopropanethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-acetylamino-4-carbamoylthiobutyrate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]2-hydroxy-2-methylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclopentanecarbonylamino)phenyl]thioacetate; S-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclopentanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate; O-methyl S-[2-(1-isopentylcyclohexanecarbonylaminophenyl monothiocarbonate; S-[2-(1-methylcyclohexanecarbonylamino)phenyl]S-phenyldithiocarbonate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]N-phenylthiocarbamate; S-[2-(pivaloylamino)-4-trifluoromethylphenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(2-cyclohexylpropionylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-pentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclopropylmethylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-cyclohexylmethylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopropylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcycloheptanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[4,5-dichloro-2-(1-isopentylcyclobutanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-nitrophenyl]2,2-dimethylthiopropionate; S-[4-cyano-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[5-

chloro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; S-[4,5-difluoro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]2,2-dimethylthiopropionate; S-[5-fluoro-2-(1-isopentylcyclohexanecarbonylamino)phenyl]2,2-dimethylthiopropionate; bis-[4,5-dichloro-2-(1-isopentylcyclohexanecarbonylamino)-phenyl]disulfide; 2-tetrahydrofurylmethyl 2-(1-isopentylcyclohexanecarbonylamino)phenyl disulfide; N-(2-mercaptophenyl)-1-ethylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-propylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-butylcyclohexanecarboxamide; N-(2-mercaptophenyl)-1-isobutylcyclohexanecarboxamide; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]cyclohexanethiocarboxylate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]thiobenzoate; S-[2-(1-isopentylcyclohexanecarbonylamino)phenyl]5-carboxythiopentanoate; S-[2-(1-isopentylcyclohexanecarbonylamino)-4-methylphenyl]thioacetate; bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide; N-(2-mercaptophenyl)-1-(2-ethylbutyl)cyclohexanecarboxamide; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-methylthiopropionate; S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]1-acetylpiperidine-4-thiocarboxylate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]thioacetate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2,2-dimethylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]methoxythioacetate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]2-hydroxy-2-methylthiopropionate; S-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]4-chlorophenoxythioacetate; S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]4-chlorophenoxythioacetate; or S-[2-(1-isobutylcyclohexanecarbonylamino)phenyl]-1-acetyl-piperidine-4-thiocarboxylate; or a pharmaceutically acceptable salt of any of the foregoing.

19. The composition for use according to claim 17 or 18, wherein the CETP inhibitor is to be administered to the subject in an amount ranging from 100 mg to 2400 mg per day.

~~20. The composition for use according to claim 19, wherein the CETP inhibitor is to be administered to the subject in an amount ranging from 100 mg to 1800 mg per day.~~

~~21. The composition for use according to claim 20, wherein the CETP inhibitor is to be administered to the subject in an amount ranging from 300 mg to 900 mg per day.~~

~~22. The composition for use according to claim 21, wherein the CETP is to be administered to the subject in an amount of 600 mg per day.~~

~~23. The composition for use according to any one of claims 19-22, wherein an effective amount of an antidiabetic agent is to be further administered to the subject.~~

~~24. The composition for use according to claim 23, wherein the antidiabetic agent is metformin, a sulfonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, GLP-1, a GLP-1 analogue, insulin, an insulin analogue, or a DPP-IV inhibitor, or a pharmaceutically acceptable salt thereof.~~

~~25. The composition for use according to any one of claims 17-22, wherein the subject undergoes treatment with an antidiabetic agent.~~

~~26. The composition for use according to claim 25, wherein the antidiabetic agent is metformin, a sulfonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, GLP-1, a GLP-1 analogue, insulin, an insulin analogue, or a DPP-IV inhibitor, or a pharmaceutically acceptable salt thereof.~~

~~27. The composition for use according to any one of claims 17-26, wherein the subject has an HbA1c level that is equal to or greater than 6.5% of whole blood.~~

~~28. The composition for use according to any one of claims 17-27, wherein the subject has an HbA1c level that is equal to or greater than 7.0% of whole blood.~~

~~29. The composition for use according to any one of claims 17-28, wherein the subject has an HbA1c level that is equal to or greater than 7.5% of whole blood.~~

~~30. The composition for use according to any one of claims 17-29, wherein the subject has a fasting plasma glucose level that is equal to or greater than 126 mg/dL.~~

~~31. The composition for use according to any one of claims 17-30, wherein the subject is an adult human.~~

~~32. The composition for use according to any one of claims 17-30, wherein the subject is a pediatric human.~~

14. Use of dalcetrapib in the preparation of a medicament for reducing risk of new onset diabetes in a subject in need thereof.

15. The use of claim 14, wherein the dalcetrapib is to be administered to the subject in an amount ranging from 100 mg to 2400 mg per day.

16. The use of claim 15, wherein the dalcetrapib is to be administered to the subject in an amount ranging from 100 mg to 1800 mg per day.

17. The use of claim 16, wherein the dalcetrapib is to be administered to the subject in an amount ranging from 300 mg to 900 mg per day.

18. The use of claim 17, wherein the dalcetrapib is to be administered to the subject in an amount of 600 mg per day.

19. The use of any one of claims 14-18, wherein the subject is an adult human.

20. The use of any one of claims 14-18, wherein the subject is a pediatric human.